Policy Statements

Genetic Alliance is called on periodically to testify before congressional committees, advisory committees and other deliberative bodies. In addition, Genetic Alliance actively leverages the voices of its network in formal communication with government officials and agencies. Here are some of the statements presented:

Natasha Bonhomme presents public comments to HIT Policy Committee regarding inclusion of NBS as an area of focus for meaningful use for 2013 – July 29, 2010

Sharon Terry Testifies at Public Access to Federally-Funded Research Hearing – July 29, 2010

Sharon Terry Testifies about Increasing Oversight of Laboratory Developed Tests (LDTs)– July 19-20, 2010

Genetic Alliance submits recommendations regarding the Retention and Use of Residual Dried Blood Spot Specimens after Newborn Screening – July 1, 2010

Sharon Terry offers perspectives on the development of therapies and diagnostics to inform the work of the FDA's committee for rare diseases –
June 29-30, 2010

Sharon Terry Testifies at June 29–30 FDA Public Hearing: Development of Articles for Rare Diseases – June 29, 2010

Sharon Terry provides testimony on the topic of Genetic Information to the National Committee on Vital and Health Statistics (NCVHS) – June 15, 2010

Genetic Alliance Opposes Legislation to Ban Gene Patenting – April 30, 2010

Sharon Terry Testifies at the House Committee on Science and Technology – February 24, 2010

Genetic Alliance Asks FDA for Oversight of Advanced Diagnostic Tests and Proposed IVDMIA Guidance – February 2, 2010

Genetic Alliance Speaks at FDA Transparency Task Force Meeting – June 24, 2009

Sharon Terry Testifies at House Appropriations Committee Hearing – March 18, 2009